83 related articles for article (PubMed ID: 18520303)
1. K-ras as a target for lung cancer therapy.
Adjei AA
J Thorac Oncol; 2008 Jun; 3(6 Suppl 2):S160-3. PubMed ID: 18520303
[TBL] [Abstract][Full Text] [Related]
2. Discussion - EGFR-targeted agents.
J Thorac Oncol; 2008 Jun; 3(6 Suppl 2):S150-1. PubMed ID: 18520301
[No Abstract] [Full Text] [Related]
3. K-ras as a target for cancer therapy.
Friday BB; Adjei AA
Biochim Biophys Acta; 2005 Nov; 1756(2):127-44. PubMed ID: 16139957
[TBL] [Abstract][Full Text] [Related]
4. Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
Riely GJ
J Thorac Oncol; 2008 Jun; 3(6 Suppl 2):S146-9. PubMed ID: 18520300
[TBL] [Abstract][Full Text] [Related]
5. Sorafenib in lung cancer: clinical developments and future directions.
Blumenschein G
J Thorac Oncol; 2008 Jun; 3(6 Suppl 2):S124-7. PubMed ID: 18520294
[TBL] [Abstract][Full Text] [Related]
6. [Targeting KRAS pathway in NSCLC therapy].
Le Moulec S; Loriot Y; Soria JC
Bull Cancer; 2009 Dec; 96 Suppl():S69-74. PubMed ID: 20034872
[TBL] [Abstract][Full Text] [Related]
7. Targeted therapy for the treatment of advanced non-small cell lung cancer: a review of the epidermal growth factor receptor antagonists.
Silvestri GA; Rivera MP
Chest; 2005 Dec; 128(6):3975-84. PubMed ID: 16354869
[TBL] [Abstract][Full Text] [Related]
8. P53 and K-ras mutations are frequent events in microscopically negative surgical margins from patients with nonsmall cell lung carcinoma.
Jassem J; Jassem E; Jakóbkiewicz-Banecka J; Rzyman W; Badzio A; Dziadziuszko R; Kobierska-Gulida G; Szymanowska A; Skrzypski M; Zylicz M
Cancer; 2004 May; 100(9):1951-60. PubMed ID: 15112277
[TBL] [Abstract][Full Text] [Related]
9. Expression of TLR9 in tumor-infiltrating mononuclear cells enhances angiogenesis and is associated with a worse survival in lung cancer.
Belmont L; Rabbe N; Antoine M; Cathelin D; Guignabert C; Kurie J; Cadranel J; Wislez M
Int J Cancer; 2014 Feb; 134(4):765-77. PubMed ID: 23913633
[TBL] [Abstract][Full Text] [Related]
10. The effect of gefitinib on B-RAF mutant non-small cell lung cancer and transfectants.
Toyooka S; Uchida A; Shigematsu H; Soh J; Ogino A; Takata M; Kiura K; Ouchida M; Kosaka T; Aoe M; Mitsudomi T; Date H
J Thorac Oncol; 2007 Apr; 2(4):321-4. PubMed ID: 17409805
[TBL] [Abstract][Full Text] [Related]
11. [Personalized treatment in non-small cell lung cancer].
Campos-Parra AD; Cruz-Rico G; Arrieta O
Rev Invest Clin; 2012; 64(4):377-86. PubMed ID: 23227588
[No Abstract] [Full Text] [Related]
12. Somatic mutations of the epidermal growth factor receptor and non-small-cell lung cancer.
Zhang X; Chang A
J Med Genet; 2007 Mar; 44(3):166-72. PubMed ID: 17158592
[TBL] [Abstract][Full Text] [Related]
13. Rationale for treatment and study design of tailor: a randomized phase III trial of second-line erlotinib versus docetaxel in the treatment of patients affected by advanced non-small-cell lung cancer with the absence of epidermal growth factor receptor mutations.
Farina G; Longo F; Martelli O; Pavese I; Mancuso A; Moscetti L; Labianca R; Bertolini A; Cortesi E; Farris A; Fagnani D; Locatelli MC; Valmadre G; Ardizzoia A; Tomirotti M; Rulli E; Garassino MC; Scanni A
Clin Lung Cancer; 2011 Mar; 12(2):138-41. PubMed ID: 21550561
[TBL] [Abstract][Full Text] [Related]
14. Expression of insulin-like growth factor 1 receptor (IGF-1R) predicts poor responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer patients harboring activating EGFR mutations.
Yeo CD; Park KH; Park CK; Lee SH; Kim SJ; Yoon HK; Lee YS; Lee EJ; Lee KY; Kim TJ
Lung Cancer; 2015 Mar; 87(3):311-7. PubMed ID: 25617986
[TBL] [Abstract][Full Text] [Related]
15. [Gefitinib as targeted treatment for non-small-cell lung cancer].
Knuuttila A; Karjalainen EM; Rouhos A; Mali P
Duodecim; 2005; 121(3):267-72. PubMed ID: 15787284
[No Abstract] [Full Text] [Related]
16. Sorafenib inhibits non-small cell lung cancer cell growth by targeting B-RAF in KRAS wild-type cells and C-RAF in KRAS mutant cells.
Takezawa K; Okamoto I; Yonesaka K; Hatashita E; Yamada Y; Fukuoka M; Nakagawa K
Cancer Res; 2009 Aug; 69(16):6515-21. PubMed ID: 19638574
[TBL] [Abstract][Full Text] [Related]
17. A fast and convenient new technique to detect the therapeutic target, K-ras mutant, from peripheral blood in non-small cell lung cancer patients.
Tsao DA; Yang MJ; Chang HJ; Yen LC; Chiu HH; Hsueh EJ; Chen YF; Lin SR
Lung Cancer; 2010 Apr; 68(1):51-7. PubMed ID: 19589613
[TBL] [Abstract][Full Text] [Related]
18. A novel molecular staging protocol for non-small cell lung cancer.
Miyake M; Adachi M; Huang C; Higashiyama M; Kodama K; Taki T
Oncogene; 1999 Apr; 18(14):2397-404. PubMed ID: 10327061
[TBL] [Abstract][Full Text] [Related]
19. Dual inhibition of the epidermal growth factor receptor with cetuximab, an IgG1 monoclonal antibody, and gefitinib, a tyrosine kinase inhibitor, in patients with refractory non-small cell lung cancer (NSCLC): a phase I study.
Ramalingam S; Forster J; Naret C; Evans T; Sulecki M; Lu H; Teegarden P; Weber MR; Belani CP
J Thorac Oncol; 2008 Mar; 3(3):258-64. PubMed ID: 18317068
[TBL] [Abstract][Full Text] [Related]
20. Clinical experience with the HER1/EGFR tyrosine kinase inhibitor erlotinib.
Sandler A
Oncology (Williston Park); 2003 Nov; 17(11 Suppl 12):17-22. PubMed ID: 14682119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]